dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Iranzo Gómez, Patricia |
dc.contributor.author | Pardo Aranda, Nuria |
dc.contributor.author | Callejo Perez, Ana |
dc.contributor.author | Cedres Perez, Susana |
dc.contributor.author | Martínez Marti, Alexandre |
dc.contributor.author | Navarro Mendivil, Alejandro |
dc.contributor.author | Soleda, Mireia |
dc.contributor.author | Jiménez Flores, José Antonio |
dc.contributor.author | Hernandez Losa, Javier |
dc.contributor.author | Vivancos Prellezo, Ana |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Amat, Ramon |
dc.contributor.author | Carbonell, Caterina |
dc.contributor.author | Frigola Rissech, Joan |
dc.date.accessioned | 2022-09-06T08:56:57Z |
dc.date.available | 2022-09-06T08:56:57Z |
dc.date.issued | 2022-04 |
dc.identifier.citation | Frigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, et al. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. J Immunother Cancer. 2022 Apr;10(4):e004197. |
dc.identifier.issn | 2051-1426 |
dc.identifier.uri | https://hdl.handle.net/11351/8030 |
dc.description | Immunoteràpia; Càncer de pulmó; Biomarcadors tumorals |
dc.description.sponsorship | This work was supported by Merck Healthcare KGaA, Darmstadt, Germany (Grant for Oncology Innovation to the Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain), Fundación Cientifica Asociación Española Contra el Cancer-AECC (grant number GCB14142170 to EF); the Catalan Government/AGAUR (2017–SGR–1738 to EF). Merck Healthcare KGaA reviewed the manuscript for medical accuracy only before journal submission. |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | Journal for ImmunoTherapy of Cancer;10(4) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Anomalies cromosòmiques |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Chromosome Aberrations |
dc.title | High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/jitc-2021-004197 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | aberraciones cromosómicas |
dc.relation.publishversion | http://dx.doi.org/10.1136/jitc-2021-004197 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Frigola J, Carbonell C, Soleda M, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Irazno P, Pardo N, Callejo A, Cedres S, Martinez-Marti A, Navarro A] Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Jimenez J] Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Hernandez-Losa J] Servei de Patologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Vivancos A] Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Felip E] Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 35477861 |
dc.identifier.wos | 000788620500001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |